By Pooja Toshniwal Paharia Reviewed by Susha Cheriyedath, M.Sc. May 31 2026 New Alzheimer’s drugs are raising hopes, but modest benefits, ARIA safety risks, high costs, and regulatory disagreements show how uncertain the path to meaningful treatment remains. From hope to uncertainty: regulating novel drugs for Alzheimer's disease . Image Credit: ER Pictures / Shutterstock A recent World Report published in  The Lancet examines the evolving therapeutic landscape and regulatory hurdles